Each tablet contains:
- Tenofovir Disoproxil Fumarate 300 mg
- Emtricitabine 200mg
Do not use TENMAC-EM for pre-exposure prophylaxis in individuals with unknown or positive HIV-1 status. TENMAC-EM should be used in HIV-infected patients only in combination with other anti-retroviral agents.
In HIV1 infected patients, the most common adverse reactions (incidence greater than or equal to 10%) are diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash. In HIV-1 uninfected individuals in PrEP trials, adverse reactions that were reported by more than 2% of TENMAC-EM subjects and more frequently than by placebo subjects were headache, abdominal pain and weight decreased.
HDPE Bottle packs of 30 tablets and packed in a unit carton along with package insert.
SHELF LIFE AND STORAGE:
507-508, 5th Floor, The Emporio by Kunj, Opposite 4D Square Mall, Near Vishwakarma Engineering College, Visat-Gandhinagar Highway, Chandkheda, Ahmedabad, Gujarat, 382424, India